ReviewHematology/oncology clinics of North America2024
Merkel Cell Carcinoma.
Review in Hematology/oncology clinics of North America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- [Line-field confocal optical coherence tomography in the diagnostics and treatment of recurrent Merkel cell carcinoma in the scalp].Dermatologie (Heidelberg, Germany) · 2026Article
- Article
- [Merkel cell carcinoma: current surgical approaches and multidisciplinary treatment].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- No Association Between Radiation Dose and Clinical Outcomes in Merkel Cell Carcinoma in the Veteran Population.Advances in radiation oncology · 2026Article
- Advanced Merkel cell carcinoma resulting in palliative amputation.JAAD case reports · 2026Article
- Complete metabolic response in stage IV Merkel cell carcinoma after combined avelumab and radiotherapy: a case report suggestive of an abscopal effect.Frontiers in oncology · 2026Article
- Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges.Head & neck · 2025Review
- Article
- Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma.Cancers · 2025Article
- Viral zoonosis and human cancer: a perspective.Infectious agents and cancer · 2025Review
- Understanding Merkel Cell Carcinoma: Pathogenic Signaling, Extracellular Matrix Dynamics, and Novel Treatment Approaches.Cancers · 2025Review
- Optimizing surgical margins in the treatment of eyelid Merkel cell carcinoma: a tertiary center experience and literature review.Frontiers in ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is highly radiosensitive and immunogenic. Immunotherapy is the primary treatment of advanced disease, and immune checkpoint inhibitors show promise as neoadjuvant or adjuvant therapy in patients with high-risk resectable MCC. Emerging biomarkers of tumor burden are becoming increasingly important in identifying high-risk patients and in post-treatment surveillance. Further research is needed to determine the optimal duration of anti-PD-(L)1 treatment and second-line options for patients with MCC refractory to immunotherapy. This review covers the characteristics and management of MCC including recent innovations and areas of active investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.